Oscar Health (OSCR) AI Stock Analysis

• Market Cap: $4.90B
• Dividend Yield: N/A
• Average Volume (3M): 17.82M
• Price to Earnings (P/E): 49.6
• Beta (1Y): 0.90
• Revenue Growth: 48.29%
• EPS Growth: -1436.25%
• Country: US
• Employees: 2,400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Plans
• EPS (TTM): -0.89
• Shares Outstanding: 223,044,000
• 10 Day Avg. Volume: 18,659,710
• 30 Day Avg. Volume: 17,817,517
• PEG Ratio: -1.17
• Price to Book (P/B): 3.19
• Price to Sales (P/S): 0.35
• P/FCF Ratio: 3.40
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 0.57
• Enterprise Value/Gross Profit: 0.57
• Enterprise Value/Ebitda: 29.19
• 1Y Price Target: $10.67
• Price Target Upside: -43.75% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 8

• Rating: 73 Outperform
• Price Target: $19.00 ▲(0.16% Upside)

Oscar Health's strong financial performance and positive technical indicators are the primary drivers of its stock score. However, the negative P/E ratio and operational challenges highlighted in the earnings call weigh down the overall score. The company's strategic initiatives and future profitability goals provide a cautiously optimistic outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market expansion and product adoption, supporting long-term business sustainability.

Membership Increase

Growing membership base enhances revenue potential and market presence, reinforcing Oscar Health's competitive position.

SG&A Efficiency

Improved SG&A efficiency reflects better cost management, contributing to long-term profitability and operational resilience.

Negative Factors

Increased Medical Loss Ratio (MLR)

Rising MLR indicates higher claims costs, which can pressure margins and challenge profitability if not managed effectively.

Operational Losses

Operational losses highlight ongoing financial challenges, potentially impacting cash flow and delaying profitability goals.

Higher Risk Adjustment Payable

Increased risk adjustment payable can strain financial resources, affecting cash management and financial stability.

Oscar Health Business Overview & Revenue Model

Company Description

Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payor clients to engage with members and patients. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

How the Company Makes Money

Oscar Health generates revenue primarily through premiums collected from policyholders who enroll in its health insurance plans. The company earns money by charging monthly premiums to individuals and families for coverage, as well as from employer contributions in the case of group plans. Oscar also receives reimbursement from the federal government for Medicare Advantage members. Additional revenue streams may include ancillary services, such as telehealth offerings, and value-based care arrangements that incentivize Oscar to improve patient health outcomes while managing costs. Key partnerships with health care providers and technology platforms further enhance Oscar's ability to deliver value and potentially increase its earnings.

Oscar Health Financial Statement Overview

Summary

Oscar Health shows a strong financial trajectory with significant revenue growth, improved profitability metrics, and robust cash flow generation. The balance sheet is solid with low leverage, although the equity ratio indicates room for improvement.

Income Statement

Oscar Health has demonstrated a strong revenue growth trajectory, with a significant increase in total revenue from $4.1 billion in 2022 to $10.08 billion in TTM (Trailing-Twelve-Months) 2025. The gross profit margin remains robust at 100%, indicating efficient cost management. Net profit margin has improved from negative figures to 1.22% in TTM 2025, showing progress towards profitability. EBIT and EBITDA margins have also improved, reflecting better operational efficiency.

Balance Sheet

The company's balance sheet shows a solid equity base, with stockholders' equity rising from negative in 2020 to $1.33 billion in TTM 2025. The debt-to-equity ratio is low at 0.22, indicating conservative leverage. Return on equity has turned positive, reflecting enhanced profitability. However, the equity ratio is at 22.81%, suggesting potential room for improvement in equity financing.

Cash Flow

Oscar Health has shown strong cash flow generation, with free cash flow increasing from negative figures to $1.19 billion in TTM 2025. The free cash flow to net income ratio is healthy, indicating efficient cash management. Operating cash flow to net income ratio is high, demonstrating the company's ability to convert earnings into cash effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.08B	9.18B	5.86B	4.13B	1.92B	589.64M
Gross Profit	10.08B	9.18B	5.86B	4.13B	1.92B	589.64M
EBITDA	198.05M	89.31M	-212.00M	-572.17M	-551.25M	-390.98M
Net Income	123.33M	25.43M	-270.73M	-606.27M	-572.61M	-406.82M
Balance Sheet
Total Assets	5.84B	4.84B	3.60B	4.53B	3.32B	2.27B
Cash, Cash Equivalents and Short-Term Investments	2.99B	2.15B	2.56B	2.96B	1.69B	1.19B
Total Debt	299.75M	299.56M	298.78M	298.00M	0.00	142.49M
Total Liabilities	4.51B	3.82B	2.80B	3.63B	440.02M	3.57B
Stockholders Equity	1.33B	1.01B	803.97M	890.38M	1.39B	-1.30B
Cash Flow
Free Cash Flow	1.19B	950.30M	-297.74M	351.34M	-207.63M	208.71M
Operating Cash Flow	1.22B	978.19M	-272.16M	380.35M	-181.75M	222.73M
Investing Cash Flow	-1.26B	-1.39B	577.19M	-226.52M	-774.51M	-344.71M
Financing Cash Flow	45.95M	68.39M	6.45M	301.11M	1.24B	611.71M

Oscar Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSCR, the sentiment is Positive. The current price of 18.97 is above the 20-day moving average (MA) of 18.31, above the 50-day MA of 16.22, and above the 200-day MA of 15.23, indicating a bullish trend. The MACD of 0.70 indicates Positive momentum. The RSI at 54.86 is Neutral, neither overbought nor oversold. The STOCH value of 50.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSCR.

Oscar Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OSCR	73 Outperform	$4.90B	49.61	-14.04%	―	48.29%	-1436.25%
MOH	73 Outperform	9.86B	8.97	24.55%	―	16.12%	10.99%
CNC	70 Outperform	16.06B	8.08	7.49%	―	12.96%	-23.25%
HUM	70 Outperform	31.01B	19.39	8.64%	1.37%	9.88%	-7.25%
ALHC	63 Neutral	3.38B	-62.76	-128.23%	―	49.46%	66.89%
CLOV	50 Neutral	1.54B	-34.52	0.00%	―	-4.87%	66.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Oscar Health Corporate Events

Oscar Health to Reaffirm 2025 Guidance at Conference

Oscar Health, Inc. announced its participation in the 2025 Wells Fargo Healthcare Conference on September 3, 2025. During the event, the company plans to reaffirm its updated full-year 2025 guidance, which was initially shared in its preliminary financial results for the second quarter of 2025. This move is likely to impact the company’s operations by reinforcing its financial outlook and could influence stakeholder confidence.